Allogene Therapeutics ALLO
NASDAQ ALLO
$1.54 -0.06 (-3.75%)
At close: Oct 1, 2026 · 4:00 PM EDT

Allogene Therapeutics (ALLO) Accumulated Depreciation (2018 - 2019)

Updated

Allogene Therapeutics (ALLO) posted Accumulated Depreciation of $1.59 million for Q1 2019, up 51.9% from the prior quarter.

Analysis

Allogene Therapeutics (ALLO) Accumulated Depreciation (2018 - 2019) Analysis & Trends

At the end of FY2018, Allogene Therapeutics' Accumulated Depreciation came in at $1.05 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Allogene Therapeutics 552.55 Mn 552.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 1.59 Mn
Dec 31, 2018 1.05 Mn
API Access

Allogene Therapeutics Accumulated Depreciation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-depreciation&ticker=ALLO&period=max&api_key=YOUR_API_KEY